{
    "title": "103_hr1926",
    "content": "The \"National Narcotics Leadership Act Amendments of 1993\" allows the Director to request funding for specific initiatives in line with the President's priorities for the National Drug Control Strategy. Additionally, there are amendments regarding the implementation of the National Drug Control Strategy. SEC. 3. REPORT ON REPROGRAMMING; OFFICE PERSONNEL RESTRICTION.\n\nThe Director must report quarterly to Congress on any reprogramming or transfer of funds over $5,000,000 for National Drug Control Program activities. Additionally, Federal officers in the Office of National Drug Control Policy appointed by the President cannot engage in Federal election campaign activities, with exceptions for making contributions to candidates.\n\nSEC. 4. NATIONAL DRUG CONTROL STRATEGY OUTCOME MEASURES. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy, assessing reduction of drug use in various populations and workplaces. The evaluation includes assessing drug availability reduction by measuring quantities of cocaine, heroin, and marijuana available in the US, amount of drugs entering the country, hectares of poppy and coca cultivated and destroyed, drugs seized, labs destroyed, changes in drug price and purity. The evaluation also includes assessing the reduction of consequences of drug use and availability, estimating burdens on hospital emergency rooms, national healthcare costs associated with drug use, and the effectiveness of Federal technology programs in improving drug detection capabilities at US ports of entry. The evaluation includes assessing drug-related services, national healthcare costs, drug-related crime, and the status of drug treatment in the United States. This involves determining public and private treatment capacity, including data on intravenous drug users and pregnant women. The evaluation assesses drug treatment services in the United States, including treatment capacity for intravenous drug users and pregnant women, the number of beneficiaries, and the success of treatment programs. It also evaluates the quality of treatment programs, qualifications of personnel, and admission processes. The Director is required to assess the quality of drug use measurement instruments, coverage of national drug use measurement techniques, and actions to address deficiencies in drug use measurement. The Director is tasked with assessing drug use measurement instruments, identifying deficiencies, and proposing remedies to improve treatment availability. Federal agencies collecting drug-related information must cooperate with the Director. The Director must report on drug use and availability in the US with each National Drug Control Strategy. The Director is required to report to the President and Congress on the assessment of drug use and availability in the United States, including the effectiveness of various programs in reducing drug use and availability. SEC. 5 amends Section 402(a)(7) of title 50, United States Code to include the Director of the Office of National Drug Control Policy as a member of the National Security Council. SEC. 6 establishes the Counter-Drug Technology Assessment Center. The National Narcotics Leadership Act of 1988 is amended to include support for technology in drug treatment and assistance to the Office of National Drug Control Policy. The Director of the Advanced Research Project Agency will provide assistance to the Office of National Drug Control Policy. The National Narcotics Leadership Act of 1988 is amended by repealing and redesignating certain sections. SEC. 7. The Director may pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8. Authorization of appropriations for fiscal year 1994. SEC. 9. The Office of National Drug Control Policy terminates on September 30, 1994."
}